Background: Dilantin sodium (phenytoin) is an antiepileptic drug, which is routinely used to control generalized tonic clonic seizure and partial seizure episodes. A few case reports of oral squamous cell carcinomas arising from regions of phenytoin induced gingival overgrowth (GO), and overexpression of mitogenic factors and p53 have presented this condition as a pathology with potential to transform into malignancy. We recently investigated the genetic status of p53 and H-ras, which are known to be frequently mutated in Indian oral carcinomas in GO tissues and found them to only contain wild type sequences, which suggested a non-neoplastic nature of phenytoin induced GO. However, besides p53 and H-ras, other oncogenes and tumor suppressors such as PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1, are frequently altered in oral squamous cell carcinoma, and hence are required to be analyzed in phenytoin induced GO tissues to be affirmative of its non-neoplastic nature.
Methods: 100ng of chromosomal DNA isolated from twenty gingival overgrowth tissues were amplified with primers for exons 9 and 20 of PIK3CA, exons 1α, 1β and 2 of p16INK4a and p14ARF, and exon 2 of p21Waf1/Cip1, in independent reactions. PCR amplicons were subsequently gel purified and eluted products were sequenced.
Results: Sequencing analysis of the twenty samples of phenytoin induced gingival growth showed no mutations in the analyzed exons of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1.
Conclusion: The present data indicate that the mutational alterations of genes, PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 that are frequently mutated in oral squamous cell carcinomas are rare in phenytoin induced gingival growth. Thus the findings provide further evidence that phenytoin induced gingival overgrowth as a non-neoplastic lesion, which may be considered as clinically significant given the fact that the epileptic patients are routinely administered with phenytoin for the rest of their lives to control seizure episodes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7314/apjcp.2013.14.5.2743 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis.
BDJ Open
March 2025
Bahrain Defence Force Royal Medical Services, Riffa, Kingdom of Bahrain.
Background: Drug-associated gingival disorders can negatively impact on oral health. This study aimed to utilize the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) to comprehensively assess the associations between medications and specific gingival disorders.
Methods: Data were extracted from the USFDA AERS from 2004-2024 using Preferred Terms for eight gingival disorders.
The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals.
Arch Toxicol
March 2025
Division of Systems Medicine, Jacqui Wood Cancer Centre, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK.
A large number of drugs and compounds produced by the chemical and agrochemical industry, often referred to as 'non-genotoxic carcinogens' (NGC), score as tumour promotors in rodent models. It is unclear whether these compounds act similarly in humans. The most extensively investigated compounds have been the anti-convulsive drugs, phenobarbital (PB), and phenytoin.
View Article and Find Full Text PDFContribution of brain pericytes to neuroinflammation following repetitive head trauma.
J Inflamm (Lond)
March 2025
The Roskamp Institute, Sarasota, FL, USA.
Background: Neuroinflammation is a prominent pathological hallmark of traumatic brain injury (TBI) and glia cells have been widely characterized in the onset or progression of brain inflammation. While an effect of inflammation on cerebrovascular breakdown has been observed, little is known about the specific contribution of brain pericytes to the inflammatory response in TBI. Here, we focused on studying the pericyte response to inflammatory stimuli commonly found in the brain following TBI.
View Article and Find Full Text PDFPaxlovid-induced tacrolimus toxicity in a 16-year-old male with steroid-resistant nephrotic syndrome.
Pediatr Nephrol
February 2025
Division of Nephrology, Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX, USA.
In December 2021, the Federal Drug Administration (FDA) approved emergency use authorization of nirmatrelvir-ritonavir (Paxlovid) to prevent serious SARS-CoV-2 infections in high-risk patient populations. We present the case of a 16-year-old male with steroid-resistant nephrotic syndrome who developed tacrolimus toxicity after initiation of Paxlovid therapy. The ritonavir component strongly inhibits CYP3A4 enzymes, thereby leading to the accumulation of tacrolimus in the blood.
View Article and Find Full Text PDFPrescriptions of CYP3A4- and P-gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention.
Br J Clin Pharmacol
February 2025
Research Centre for Digital Medicine, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Direct oral anticoagulants (DOACs) are frequently used for the treatment and prevention of ischaemic stroke in patients with non-valvular atrial fibrillation. Compared to vitamin K antagonists, DOACs have significant advantages, although their drug-drug interaction (DDI) profile may complicate drug efficacy and safety. This narrative review addresses the clinical challenges posed by these DDIs and the potential pharmacological alternatives and monitoring strategies available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!